Overview
Curve Biosciences, based in San Francisco, United States, has raised $40M in a Series A round on October 29, 2025, with participation from Luma Group. The company this is our Whole-Body Atlas. The round will be used to accelerate product development, expand the team, and scale go-to-market operations.
Operating in the biotechnology research sector, Curve Biosciences is positioned to capitalize on growing demand for innovative solutions in this space. The company was founded in 2022 by Ritish Patnaik. Ritish brings deep domain expertise and a track record of execution that attracted investor confidence in this round. With fresh capital, the company is expected to invest heavily in R&D and talent acquisition, signaling a period of aggressive growth ahead.
Market Outlook
The successful raise validates Curve Biosciences's approach and market opportunity. Industry analysts note that companies at this funding stage typically grow headcount by 40-60% within 12 months and make significant technology purchasing decisions in the first quarter post-funding. This makes Curve Biosciences's leadership team particularly valuable contacts for B2B outreach in the near term.
Why contact Curve Biosciences now
Curve Biosciences's $40M Series A raise signals serious investor confidence in their biotechnology research play. In the first 90 days post-funding, startups are 3x more likely to respond to outreach and evaluate new partnerships. Their team is hiring, their budget is unlocked, and they need solutions yesterday.
Founders & Contacts
Investors
Company Facts
| Company | Curve Biosciences |
| Amount Raised | $40M |
| Funding Round | Series A |
| Date Raised | October 29, 2025 |
| Founded | 2022 |
| Industry | Biotechnology Research |
| Founders | Ritish Patnaik |
| HQ Location | San Francisco, United States |
Get Verified Founder Emails
Access verified email addresses and contact details for Curve Biosciences's founders and thousands of other funded startups.
Start Free Trial